Corrigendum to "Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: Results from a prospective multicenter randomized study" [J Hepatol 44 (2006) 710-716] (DOI:10.1016/j.jhep.2005.12.010);Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: Results from a prospective multicenter randomized study

Journal of Hepatology

Volumn 44, Issue 4, 2006, Pages 710-716

  Lladó, Laura ^a   Xiol, Xavier ^a   Figueras, Joan ^a   Ramos, Emilio ^a   Memba, Roberto ^a   Serrano, Teresa ^a   Torras, Jaume ^a   Garcia Gil, Agustin ^b   Gonzalez Pinto, Ignacio ^c   Castellote, Jose ^a   Baliellas, Carme ^a   Fabregat, Joan ^a   Rafecas, Antoni ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Adverse events; Liver transplantation; Rejection; Steroids

Indexed keywords

AZTREONAM; BASILIXIMAB; CYCLOSPORIN; GLYCOSYLATED HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; STEROID; TSUKUBAENOLIDE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GINGIVA HYPERTROPHY; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LIVER BIOPSY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SURVIVAL; TUMOR;

EID: 33644924656     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.05.003     Document Type: Erratum

References (26)

1. R.T.A. Padbury, B.K. Gunson, B. Dousset, S.G. Hubscher, J.A. Buckles, and J.M. Neuberger Steroid withdrawal from long-term immunosuppression in liver allografts recipients Transplantation 55 1993 789 794
2. J.P. Lerut Avoiding steroids in solid organ transplantation Transpl Int 16 2003 213 224
3. F. Conti, E. Morelon, and Y. Calmus Immunosuppressive therapy in liver transplantation J Hepatol 39 2003 664 678
4. R. Reding Steroid withdrawal in liver transplantation: benefits, risks, and unanswered questions Transplantation 70 2000 405 410
5. J.R. Lake The role of immunosuppression in recurrence of hepatitis C Liver Transpl 9 2003 S63 S66
6. P.A. Sheiner, M.E. Schartz, E. Mor, L.K. Schluger, N. Theise, and K. Kishikawa Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation Hepatology 21 1995 30 34
7. C. Wang, J. Sun, A.G.R. Sheil, G.W. McCaughan, and G.A. Bishop A short course of methylprednisolone immunosuppression inhibits both rejection and spontaneous acceptance of rat liver allografts Transplantation 72 2001 44 51
8. G. Tisone, M. Angelico, G. Palmieri, F. Pisani, L. Baiocchi, and G. Vennarecci Immunosuppression without prednisone after liver transplantation is safe and associated with normal early graft function: preliminary results of a randomized study Transpl Int 11 1998 S267 S269
9. K. Washburn, K.V. Speeg, R. Esteril, F. Cigarroa, M. Pollack, and C. Tourtellot Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil Transplantation 72 2001 1675 1679
10. J.D. Eason, S. Nair, A.J. Cohen, J.L. Blazek, and G.E. Loss Steroid-free liver transplantation using rabbit antithymocite globulin and early tacrolimus monotherapy Transplantation 75 2003 1396 1399
11. F. Filipponi, F. Callea, M. Salizzoni, G.L. Grazi, L.R. Fassati, and M. Rossi Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab+steroids or Basiliximab+ placebo, in addition to cyclosporine and azathioprine Transplantation 78 2004 1488 1495
12. O. Boillot, D.A. Mayer, K. Boudjema, M. Salizzoni, B. Gridelli, and F. Filipponi Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study Liver Transpl 11 2005 61 67
13. T. Kato, H. Yoshida, K. Sadfar, E. Martinez, S. Nishida, and J. Moon Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study Transpl Proc 37 2005 1217 1219
14. S.J. Pelletier, K. Vanderwall, M.A. Debroy, M.J. Englesbe, R.S. Sung, and J.C. Magee Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation Transpl Proc 37 2005 1214 1216
15. International Panel. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-63.
16. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-997.
17. P.J. Scheuer Classification of chronic viral hepatitis: a need for reassessment J Hepatol 13 1991 372 374
18. C.L. Liu, S.T. Fan, C.M. Lo, S.C. Chan, I.O. Ng, and C.L. Lai Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage Liver Transpl 10 2004 728 733
19. P. Neuhaus, P.A. Clavien, D. Kittur, M. Salizzoni, A. Rimola, and K. Abeywickrama Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial Liver Transpl 8 2002 132 142
20. G. Levy, P. Burra, A. Cavallari, C. Duvoux, J. Lake, and J. Mayer Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2) Transplantation 73 2002 953 959
21. R.A. Taggart, N.A. Terrault, A.J. Vardanian, A. Bostrom, and S. Feng Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation Liver Transpl 10 2004 975 985
22. N. Gómez-Manero, J.I. Herrero, J. Quiroga, B. Sangro, F. Pardo, and J.A. Cienfuegos Prognostic model for early acute rejection after liver transplantation Liver Transpl 7 2001 246 254
23. J.M. Rabkin, C.L. Corless, H.R. Rosen, and A.J. Olyaei Immunosuppression impact on long-term cardiovascular complications after liver transplantation Am J Surg 183 2002 595 599
24. M. Navasa, J. Bustamante, C. Marroni, E. González, H. Andreu, and E. Esmatjes Diabetes mellitus after liver transplantation: prevalence and predictive factors J Hepatol 25 1996 64 71
25. S. Baid, A.B. Cosimi, M.L. Farrell, D.A. Schoenfeld, S. Feng, and R.T. Chung Post-transplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality Transplantation 72 2001 1066 1072
26. M. Berenguer, J.M. Rayon, M. Prieto, V. Aguilera, D. Nicolás, and V. Ortiz Are post-transplantation protocol liver biopsies useful in the long term? Liver Transpl 7 2001 790 796